KCNQ5

Potassium voltage-gated channel subfamily KQT member 5 · Q9NR82 · KCNQ5 on Sugi Atlas →

10,600 patent compounds predicted against KCNQ5, 5,480 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Flupirtine (SCHEMBL505322)	0.58	6/20
Flupirtine (SCHEMBL505880)	0.54	6/20
Flupirtine (SCHEMBL505354)	0.51	6/20
Ezogabine (SCHEMBL20835)	1.00	5/20
Ezogabine (SCHEMBL154715)	0.98	5/20
Ezogabine (SCHEMBL155918)	0.98	5/20
SCHEMBL1226516	0.80	5/20
Flupirtine (SCHEMBL25009)	0.65	5/20
Flupirtine (SCHEMBL505535)	0.64	5/20
Flupirtine (SCHEMBL505847)	0.64	5/20
Flupirtine (SCHEMBL505446)	0.63	5/20
Flupirtine (SCHEMBL505680)	0.63	5/20
Flupirtine (SCHEMBL1649863)	0.63	5/20
Flupirtine (SCHEMBL505608)	0.62	5/20
Flupirtine (SCHEMBL505911)	0.62	5/20
Flupirtine (SCHEMBL505375)	0.61	5/20
Flupirtine (SCHEMBL505476)	0.61	5/20
Flupirtine (SCHEMBL505557)	0.61	5/20
Flupirtine (SCHEMBL505823)	0.61	5/20
Flupirtine (SCHEMBL506361)	0.61	5/20

Clinical trials — most relevant to KCNQ5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
Study to Treat Major Depressive Disorder With a New Medication	PHASE2	COMPLETED
Long QT Syndrome Screening in Newborns	PHASE2	UNKNOWN
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
A Study of JMT203 in Patients With Cancer Cachexia	PHASE1/PHASE2	RECRUITING
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085	PHASE1	RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis	PHASE1	RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Prospective Identification of Long QT Syndrome in Fetal Life	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome	nan	COMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNQ5 binder may also engage these)

Protein	Name	Similarity
P97414	—	1.000	P97414 →
Q9Z351	—	1.000	Q9Z351 →
Q9JK45	—	1.000	Q9JK45 →
Q9TTJ7	—	1.000	Q9TTJ7 →
KCNQ3	Potassium voltage-gated channel subfamily KQT member 3	1.000	landscape →
O88944	—	0.998	O88944 →
Q8K3F6	—	0.998	Q8K3F6 →
O88943	—	0.997	O88943 →
KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	0.997	landscape →
P58126	—	0.997	P58126 →
Q9MYS6	—	0.996	Q9MYS6 →
Q60610	—	0.996	Q60610 →
O70344	—	0.995	O70344 →
Q9TUI4	—	0.995	Q9TUI4 →
A7MBB4	—	0.995	A7MBB4 →
KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	0.994	landscape →
O97531	—	0.993	O97531 →
Q9D3S3	—	0.993	Q9D3S3 →
Q3UMB5	—	0.993	Q3UMB5 →
Q9Z0N7	—	0.993	Q9Z0N7 →
Q9ER47	—	0.993	Q9ER47 →
O54852	—	0.993	O54852 →
Q9FY74	—	0.993	Q9FY74 →
Q9NS40	—	0.992	Q9NS40 →
A2ARZ3	—	0.992	A2ARZ3 →
Q63099	—	0.992	Q63099 →
G3X9J0	—	0.992	G3X9J0 →
Q6I6G8	—	0.992	Q6I6G8 →
A2ANU3	—	0.992	A2ANU3 →
Q96L42	—	0.992	Q96L42 →